BamSEC and AlphaSense Join Forces
Learn More

Karyopharm Therapeutics Inc.

NASDAQ: KPTI    
Share price (1/8/25): $0.72    
Market cap (1/8/25): $89.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 6 pages 85 Wells Ave., Suite 210 | Newton, Ma 02459 December 18, 2024 Lori Macomber Dear Lori,
12/34/56
EX-10.1
from 8-K 9 pages Sixth Amendment to Lease
12/34/56
EX-10.2
from 8-K 8 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 16 pages Transition Agreement
12/34/56
EX-10.4
from 8-K 97 pages Second Omnibus Amendment to Transaction Documents
12/34/56
EX-10.3
from 8-K 26 pages Form of Registration Rights Agreement Among the Initial Investors Party Hereto and Karyopharm Therapeutics Inc. Dated as of May 13, 2024 Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 28 pages May 8, 2024 Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 Newton, Ma 02459 Attention: Chief Financial Officer Re: Exchange for Karyopharm Therapeutics Inc. 6.00% Convertible Senior Notes Due 2029 and Warrants to Purchase Common Stock Ladies and Gentlemen
12/34/56
EX-10.2
from 10-Q 8 pages I Am Pleased to Offer You the Position of Executive Vice President and Chief Medical Officer With Karyopharm Therapeutics Inc. (The "Company"), Reporting Directly to Richard Paulson. This Is an Important Position in the Company, and I Know It Will Be a Challenging and Exciting One. We Anticipate Your Start Date to Be on or Around 4/18/2022. Please Review the Details of Your Offer of Employment Below. 1. Compensation A. Base Salary. Your Semi-Monthly Base Salary Will Be $21,458.33 ($515,000.00, if Annualized), Subject to All Applicable Taxes and Withholdings. This Position Is Classified as Exempt According to the Fair Labor Standards Act (Flsa). B
12/34/56
EX-10.1
from 10-Q 4 pages Karyopharm Therapeutics Inc. Non-Employee Director Compensation Policy Effective May 21, 2021
12/34/56
EX-10.28
from 10-K 7 pages Karyopharm Therapeutics Inc. Annual Bonus Plan
12/34/56
EX-10.5
from 10-Q 7 pages Karyopharm Therapeutics Inc. Annual Bonus Plan
12/34/56
EX-10.4
from 10-Q 27 pages Second Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10
from 10-Q 10 pages 85 Wells Ave. Newton, Ma November 24, 2020 Michael Mano 1. Compensation
12/34/56
EX-10
from 10-Q 10 pages 85 Wells Ave. Newton, Ma June 1, 2021 Sohanya Cheng via Email A. Base Salary. Your Semi-Monthly Base Salary Will Be $16,666.67($400,000, if Annualized), Subject to All Applicable Taxes and Withholdings. This Position Is Classified as Exempt According to the Fair Labor Standards Act (Flsa). B. C
12/34/56
EX-10
from 10-Q 2 pages Material contract
12/34/56
EX-10
from 10-Q 9 pages 85 Wells Ave. Newton, Ma January 13, 2022 I Am Pleased to Offer You the Position of Senior Vice President, Strategy and Portfolio
12/34/56
EX-10
from 10-Q 2 pages August 5, 2022 Stuart Poulton
12/34/56
EX-10
from 10-Q 4 pages Amendment No. 2 to License Agreement by and Between Karyopharm Therapeutics Inc. and Berlin-Chemie AG
12/34/56
EX-10
from 10-Q 3 pages Amendment No. 1 to License Agreement by and Between Karyopharm Therapeutics Inc. and Berlin-Chemie AG
12/34/56
EX-10
from 10-K 4 pages Karyopharm Therapeutics Inc. Non-Employee Director Compensation Policy Effective May 21, 2021
12/34/56